Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment

NCT06502964 is registered in ClinicalTrials.gov with Alto Neuroscience as lead sponsor.

NCT NCT06502964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06502964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double-Blind, Placebo-Controlled Study of ALTO-101 in Patients With Schizophrenia and Cognitive Impairment
Lead sponsor
Alto Neuroscience
Phase
Phase 2
Overall status
Recruiting
Start date
June 11, 2024
Completion date
March 31, 2026
Enrollment
82 (estimated)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, schizophrenia